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GENE "THERAPY"

IS

Gene "Therapy": A Test Case for
Research with Children
M. Therese Lysaught, Ph.D.
THE CULTURAL FACE of gene therapy is that of a child. The ima~e of a
child has served as the secular icon of the mystery and promises of
human gene transfer since its inception in 1990. 1 The particular ~ace
of the child changes, determined by the mess~ge t~ be commurncated. It is the face of Ashanti De Silva, her identity long obscured
behind the veil of confidentiality, who at four years old was the fi~st \
subject enrolled in a human gene trans~er protocol with therapeutic
intent. Her identity revealed after years m the proto~ol, she stands as
a symbol of hope and promise. It is a countenance hke that of ]~cob
Sontag, his worried face gracing t~e cover of the N~w York Tzmes
Magazine drawing observers attention to the desperat10n of parents
' the salvific powers of human gene trans1er.
r 2I t 1s_t
. he u~age
.
and faith in
of an Amish child, floating surreally in a vivid sea of ultrav101.et hg~~ ·
pointing to the numinous power of human .gene transf~r and its ab1hty to transcend the most intransigent of social b~undanes. 3
Those familiar with the history of human subjects research and the
controversies surrounding recombinant DNA in the late 1970~ ~nd
1980s ought to find this iconography of particular interest. For 1.t is a
striking phenomenon: the emergence of a? entirely new modah~ of
clinical intervention, methods un~ested, nsks ~nkno~n yet publicly
feared whose earliest human subjects were children. Moreover, as
iconic: these images often function to foresta.11 criti9ue, to displace .
argument, to garner public support-and public momes-for human
gene transfer research.
.
.
. .
Despite the high visibility of children m the develop~ent an~ justification of the field of human gene transfer, the topic remams an
"orphan issue."5 A full examination of the use of child subjects in
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human gene transfer research remains beyond the scope of this essay.6
Such an account would attend to questions such as: How did this come
to pass? What social, political, and/or rhetorical factors account for the
fact that children were enrolled in human gene transfer so early in the
development of such a controversial field, in fact in only the second
clinical trial? How many children have been enrolled in clinical trials
of human gene transfer? What have these trials entailed? How have
these protocols fitted with the federal regulations and federal and professional policies governing the use of child subjects in research?
Two recent events suggest the timeliness of the investigation. First,
there is increasing public pressure to enroll children as subjects in
clinical trials. In November 1998, the Food and Drug Administration
(FDA) announced a major change in the rules governing the process
by which pharmaceutical companies will receive approval for new
medications. As will be discussed below, this change requiring companies to submit data on the safety and effectiveness of new drugs and
vaccines in children occurred largely as an effect of public, political,
and professional pressure for a more aggressive and, some argued, a
more 7just approach to developing therapies for fatal childhood diseases. At the same time, however, questions are being raised about
compliance with established guidelines and the effectiveness of public oversight of human gene transfer research. Following in the wake
of the tragic and troubling death of Jesse Gelsinger at the University
of Pennsylvania in September 1999, emerging findings suggest lack of
compliance with enrollment criteria, failure to report of adverse
events, and a deeply problematic informed-consent process. 8
As a first step toward a broader examination of the role of child subjects in human gene transfer research, this essay wiU examine the tensive interface between federal and professional guidelines governing
research with child subjects and research practice. Guidelines and
oversight mechanisms exist; how are they interpreted, operationalized,
and implemented? These questions will be examined by displaying
one particular human gene transfer protocol - one that proposed to
enroll HIV-positive children as subjects-as it negotiated the process
of oversight and approval. Focusing on a particular protocol provides
an opportunity for concrete display of the scientific, clinical, and political dimensions of human gene transfer research involving children.
At the same time, it highlights both ambiguities in the guidelines
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themselves as well as the tendency of research practice to challenge
straightforward criteria. In order to provide a framework wi~ which to
examine the protocol, I begin with a brief history and overview of current regulations and policies governing research with children as
human subjects.
CHILDREN AS RESEARCH SUBJECTS:
FEDERAL REGULATIONS AND POLICY

Two competing and legitimate tensions govern the question of
whether and how to conduct research with children. On the one
hand the historical witness of the abuse of vulnerable human subjects '
withi~ the U.S. medical system, especially in conjunction with government involvement, has justifiably led to a protectionist stance
toward research involving children. 9 Conservative, cautious safeguards are necessary to protect children, who cannot consent a~d who
may experience the burdens of medical intervention as more fnghtening and excruciating than adults, from being unduly exploited by the
interests of researchers, the desperation of their parents, and the
relentless momentum of the research imperative. As the recent FDA
ruling suggests, however, the legitimate need to safeguard pa~icular
children must be balanced with the interests of justice, particularly
the need to advance the medical care of children. These tensions
inform current federal and professional regulations and policy concerning research involving children. 10
.
The history of the federal regulations governing research on children reflects the concern to protect child subjects. Public concern
over the cases mentioned above led in part to the congressional institution, in 1974, of the National Commission for the Protection of
Human Subjects of Biomedical and Behavioral Research. In the same
year, the Department of Health, Education and Welfare (DH~W;
now known as the Department of Health and Human Services,
DHHS) issued its first regulations for the protection of human subjects in research.11 The first DHEW/DHHS regulations covering
research involving children appeared in 1978. 12 Following the counsel of the 1977 report Research Involving Children published by the
National Commission for the Protection of Human Subjects in ,
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Biomedical and Behavioral Research, 13 the DHHS published its final
regulations, providing "additional protections for children involved as
subjects in research" on March 8, 1983. These regulations became
effective on June 5, 1983, codified as 45 CFR 46, Subpart D. 14
The precepts of Subpart D have guided research on children for
the past sixteen years. These precepts distinguish five categories of
research to clarify when children may be enrolled as research subjects. These categories are: 15
S46.401

[Exempt research].

S46.404 Research not involving greater than minimal risk.
S46.405

Research involving greater than minimal risk, but presenting
the prospect of direct benefit to the individual subjects.

S46.406 Research involving greater than minimal risk and no
prospect of direct benefit to individual subjects, but likely to
yield generalizable knowledge about the subject's disorder or
condition.
S46.407

Research not otherwise approvable, which presents an
opportunity to understand, prevent, or alleviate a serious
problem affecting the health or welfare of children.

As is evident from even a brief scan of these categories, the anchoring concept of the regulations is the concept of risk, articulated operationally as "minimal risk." Only once the level of risk is established
may deliberations regarding the acceptability of enrolling children
move to assessing the prospect of benefit; correlatively, should risk be
minimal or less, the notion of benefit to individual child subjects
becomes irrelevant. As Janofsky and Starfield note: "only if the IRB
determines that a proposed project will in fact entail greater than minimal risk must its members additionally address other issues, such as
whether there is prospect of direct benefit to individual subjects. . . .
Thus, decisions about risk must be made separately from and before
any consideration of possible benefit is judged." 16
"Minimal risk" is defined earlier in the federal regulations as follows:
"'Minimal risk' means that the risks anticipated in the proposed
research are not greater, considering probability and magnitude, than
those ordinarily encountered in daily life or during the performance of
17
routine physical or psychological examinations or tests. (S46.102G)"
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The definition for "greater than minimal risk" emerges fro ·
§46.406. Research that entails "greater than minimal risk" may be pe '
mitted in certain situations, but limits are still set: 'The interventi
or procedure presents experiences to subjects that are reasonably co '.'
mensurate with those inherent in their actual or expected medical!
dental, psychological, social or educational situations."
As will be argued below, human gene transfer protocols propose
to date fall clearly entail "greater than minimal risk" and so must
considered under SS46.405, 46.406, or 46.407.
But as anyone who has sat on an institutional review board (IRB}~
knows well, determining how to categorize a specific protocol is mor~ ·
an art than a science. For it is in the concrete negotiations of IRB;'
approval that the concern for protectionism competes with the legitimate need to conduct research on children. Even before Subpart D 1
was issued, pediatricians argued that restricting research with children
would compromise pediatric medical care. As early as 1968, H. C. ;
Shirkey coined the term "therapeutic orphan," arguing that a reluc- '
tance to. tes~ t~e safety and efficacy of drugs on children could danger- .·
ously mh1b1t the development of needed pharmaceutical ;
interventions for children, handicapping pediatric medicine.18
.
Shirkey's concerns were not unfounded. As the Committee on
Drugs of the American Academy of Pediatrics (AAP) recently reported:
A survey of the 1973 Physician's Desk Reference revealed that prescribing information for 78% of medications included a disclaimer or lack
of dose information for use by children. A subsequent survey of the
1~91 Physician's Desk Reference showed that 81 % of listed drugs contained language disclaiming use in children or restricting use to certain
age groups. A survey of new molecular entities approved by the Food
and Drug Administration (FDA) from 1984 through 1989 revealed that
80% were approved without labeling for children. In 1992, 19 new
molecular entities with potential use in children were approved by the
FDA; 79% of these drugs were not labeled for use in children. In most
instances drugs are not labeled for use in children because sufficient
studies have not been conducted in children. 19

Adult studies, however, are not sufficient. As Grodin and Alpert note:
"children are not little adults." 20 The AAP concurs:
Growth, differentiation, and maturation can alter the kinetics end
organ responses, and toxicities of drugs in the newborn infant ~hild

'

'

'
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or adolescent compared to the adult. Drug studies in adult humans
may not adequately predict the pharmacokinetic, pharmacodynamic,
or toxic properties of drugs in children. When drugs have been administered to children without sufficient pharmacology studies to identify
the optimal therapeutic approach, children have occasionally suffered
severe toxic effects, including death. These toxic effects could have
been avoided with some of the drugs if appropriate dru~ studies had
1
been undertaken before their widespread use in children.

Given these significant physiological issues, coupled with the crisis in
the pharmacological armamentarium, the MP calls for children to be
included "in clinical studies of a drug when the drug offers potential
benefits to them." 22
The recommendation of the AAP recently became public policy.
Public pressure, channeled through the lobbying power of Congress
and the Clinton White House, led to the recent issue of the National
Institutes of Health (NIH) Policy and Guidelines on the Inclusion of
Children as Participants in Research Involving Human Subjects.
Effective October 1, 1998, the purpose of the policy is explicit: "to
increase the participation of children in research so that adequate data
will be developed to support the treatment modalities for disorders
and conditions that affect adults and may also affect children." 23 The
policy holds as follows:
It is the policy of the NIH that children (i.e., individuals under the age
of 21) must be included in all human subjects research, conducted by
the NIH, unless there are scientific and ethical reasons not to include
them ... proposals for research involving human subjects must include
a description of plans for including children. If children will be excluded from the research, the application or proposal must present an acceptable justification for the exclusion. . . . The inclusion of children as
subjects in research must be in compliance with all applicable subparts
of 45 CFR 46 as well as with other pertinent federal laws and regulations.

Following the lead of the NIH, on November 27, 1998, the FDA
issued new rules (effective April 1, 1999) requiring pharmaceutical
companies seeking FDA approval for new drugs and vaccines to submit data on the safety and effectiveness of these modalities in children
"if the product is likely to be used in a substantial number of pediatric
patients" or if it provides a "meaningful therapeutic benefit" over existing treatments for children of similar ages. 24 The FDA guidelines, as
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might be expected, met with strenuous objections from drug compa- '
nies, who deemed them "impractical and burdensome," costly, and,
surprisingly, "unethical, because they might put children at risk."
In the near term, then, it seems that the balance between protectionism and expansionism is shifting toward those who advocate
increased involvement of children in biomedical research. Yet even
those who recognize the need for research with children recognize
that requirements for the inclusion of children might place children
at an unacceptable risk. In light of this, a consensus has emerged
among federal, professional, and academic commentators alike confirming a long-standing precept in research with child subjects: the
necessary priority of research on adults. A survey of statements reveals
this consensus.
The 1998 NIH policy outlines a series of seven "justifications for
exclusions" by which researchers might legitimately avoid the require· ,
ment to conduct studies on children. Of these, the fifth is most perti~
nent to our discussion.

5. Insufficient data are available in adults to judge potential risk in
children (in which case one of the research objectives could be to
obtain sufficient adult data to make this judgment). While children
usually should not be the initial group to be involved in research
studies, in some instances, the nature and seriousness of the illness
may warrant their participation earlier based on careful risk and benefit analysis.
This caveat first appears in the National Commission's report, where
Recommendation 2B states:
Where appropriate, studies have been conducted first on animals and
adult humans, then on older children, prior to involving infants ....
Whenever possible, research involving risk should be conducted first
on animals and adult humans in order to ascertain the degree of risk
and the likelihood of generating useful knowledge. Sometimes this is
not relevant or possible, as when the research is designed to study disorders or functions that have no parallel in animals or adults. In such
cases, studies involving risk should be initiated on older children to the
extent feasible prior to including infants, because older children are
less vulnerable and they are better able to understand and to assent to
participation. In addition, they are more able to communicate about
any physical or psychological effects of such participation.25
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As Robert Levine notes in his commentary on the report,
"Investigators who proposed to do research on children without having first done such research on animals and/or adults will be obligated to persuade the IRB that this is necessary. Suitable justification
might be that the disorder or function to be studied has no parallel in
animals or adults." 26
Although this recommendation was not included specifically as a
regulation in Subpart D, the DHHS states in the Preamble to the
1983 regulations that it expects this recommendation to be followed. 27
In their 1994 work Children as Research Subjects, Michael A. Grodin
and Leonard H. Glantz propose a set of "Points to Consider in
Proposing or Reviewing Research Involving Children." The first of
these points asks the following questions:
I. Is the use of children as research subjects justified in this instance?
(b) if the research question can be addressed first in adults, has
research with adults been conducted?
(c) has the adult research produced results that would indicate that
the proposed research would benefit, or not be harmful to, the
children? 28
Finally, the AAP concurs: "In most cases, studies in children should
be preceded by initial clinical trials in adults to provide preliminary
pharmacokinetic, safety, and efficacy data. In some instances, drugs
intended to treat specific diseases that primarily or exclusively occur
in children may be studied initially in children."29
This prioritization is reflected in the commentary on the regulations found in the IRB Guidebook published by the NIH's Office for
Protection from Research Risks (OPRR):
Phase I Trials. The issue of Phase I drug studies deserves special consideration. The usual approach to designing drug studies involving
children as subjects is for appropriate studies to be conducted first in
animals, adults, and older children before young children are
involved as research subjects. There are some studies, however, in
which data may not be entirely generalizable from older populations,
and in which the existence of life-threatening conditions for children
are important considerations in the IRB's risk/benefit analysis. The
requirement for previous testing in adults or older children may thus
not be appropriate. Furthermore, some diseases specific to children
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may require that children be involved without data from older groups
(e.g., there is no adult model that mimics the state of HIV-infected
newborns; Wilms' tumor and various cancers such as neuroblastoma
affect infants who do not survive into older childhood). In some cases
"tandem" studies in older populations and children may be justifiable. For example, some Phase 1 studies in children might be based
on only pharmacologic safety and toxicity data (completed Phase 1
and ongoing Phase 2) but without complete effectiveness data from
trials in adults and older children. If the IRB approves a Phase 1 drug
trial, the consent document must specify what is known about the
probability that, and the degree to which, an intervention will be of
possible benefit based on all of these data. 30

ignora~ce. or o~s~uctioni.sm, or worse, the ultimate argument stopper, with 1mpenlmg the lives of dying children.
Clearly, these issues are not unique to human gene transfer
~esearch. The concrete display of the applicability of these guidelines
m the context of a human gene transfer protocol, however, simultaneously illumines issues surrounding the guidelines and issues surroundin? the conduc~ of human gene transfer research. For the purposes of
this essay, I will focus on a protocol for a Phase I trial entitled:
"Transduction of CD 34( +) Cells from the Bone Marrow of HIV-I
Infected Children: Comparative Marking by an RRE Decoy Gene
an? a .Neutral Gene." 31 An analysis of the protocol in light of the
gm~elmes as we.ll a~ a partial narrative of its progress through the
review process will highlights the issues identified above.
I was first asked to review this protocol as part of the consolidated
review process by the Recombinant DNA Advisory Committee of the
National Institutes of Health (RAC) in November 1995.32 My charge
was to determine whether or not the protocol could be approved
thr~ugh con~olidated revie~ or whether it warranted review by the
entire committee at one of its quarterly meetings. 33
.. In th~s protocol, the investigator proposed to enroll five HIV-l-pos1tive children between the ages of three and eighteen. 34 Through the
protocol, the researchers sought to "determine whether the transduced CD34+ cells engrafted and produced peripheral blood leukocytes [T cells and their progenitors] that would have a selective
survival advantage." The researchers hypothesized that the transduced
gene would make the T cells resistant to HIV infection; they would
then produce offspring T cells that would be likewise resistant to
infection. Such resistance might, in theory, slow progression of the disease course.
The protocol proposed to subject the child subjects to the following clinical procedures:

Note here the meaning of "tandem studies" as used by the OPRR:
researchers are to initiate Phase I trials in children when Phase I trials
have been concluded in adults and adult research has moved to Phase •
II trials. As we wilJ see, this is an important caveat vis-a-vis human :
gene transfer research, given that almost all human gene transfer clinical trials to date have been Phase I trials.

CHILDREN AND HUMAN GENE TRANSFER
RESEARCH: THE HIV PROTOCOL

f
While these guidelines may seem relatively straightforward and seem{'
to provide a well-crafted, prudent, and thoughtful balance betweel1;
protectionism and the legitimate need to enroll children in clinical';
trials, in practice their application is much more contested. Key::
terms and criteria of the guidelines are ambiguous to the point
admitting what seems like almost any interpretation. What counts .
"minimal risk" or, if that can be established, a "minor incremen~
over minimal risk? What constitutes a "prospect" of benefit? Is thi ·
different from a "possibility," a "hope," an "intention"? How impo 4
tant must knowledge be to be "vital"? While common sense migh·
provide relatively straightforward answers to these questions in th .
context of a particular protocol, clinical experience may often le
investigators to assess notions such as "risk," "prospect," and urgen
differently. In cases where the guidelines are so clear as to raise qu
tions about a particular research endeavor on ethical grounds, revi ·
ers and committees often find themselves assailed with charges ·

•

inclusion assessments, including phlebotomy, electroencephalogram, electrocardiogram, and chest X ray;

•
•
•

bone marrow aspirate to obtain cells for stromal growth;
preoperative screening assay;
bone marrow harvest under general anesthesia ( 10-15 cc/kg);
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•
•
•

•
•

cell transduction: CD34+ T lymphocytes were to be isolated and
transduced with two different retroviral vectors, one an anti-HIV-1
gene (L-RRE-neo) and the other a neutral marking gene (LN);
infusion of transduced cells;
overnight hospitalization;
post-"treatment" assays, including phlebotomy (approximately ten
over a two-year period); and
a possible additional one or two bone marrow aspirates .

In my (albeit brief) history with the RAC at this point, it seemed clear
that this protocol raised certain flags that might ordinarily have trig- ,
gered the full review process:

of fuller discussion. While a complete review of the protocol is beyond
the constraints of this essay, three areas are worthy of highlight: the
degree of risk presented to child subjects by the protocol; the
"prospect" of benefit to the child subjects; and ~e lack of adult d~ta.
As discussed above, the key concept anchormg the federal gmdelines is the nature and degree of risk presented to the child subjects by
the protocol. Risk ass~ssment for child subj~cts ?,1ust take,,into acc~unt
not only risks of physical harm but nonphysical burdens the sub1ects
will bear as well. In the case of children, these "burdens" take on
greater weight, as children cannot truly consent _to bea~ them. Hence,
the determination of risks and burdens for this particular protocol
would be required to address at least the following:

It was the first anti-HIV protocol presented to the RAC that proposed
to use children as research subjects. Generally, new diseases or new ,
study populations would automatically trigger full RAC review. Four
protocols following a similar strategy of intracellular replication inhi-.
bition for CD4+ or CD34+ cells had been approved for Phase I din..
ical trials in adults (9309-057, 9503-103, 9508-117, and 9511-134);
three had just been approved in 1995 (March, August, and November ,
respectively). None had yet issued data. None was referenced in the
protocol. Hence, while the RAC had reviewed HIV protocols, it had
not reviewed an HIV protocol involving children.
None had used this particular retroviral vector construct. Generally,
new vectors would trigger full RAC review. A similar RRE decoy vector had been proposed in the adult protocol approved in November
(9511-134). Other protocols had used J) similar strategy of intracellular,
replication inhibition of CD34+ or CD4+ lymphocytes of HIV-positive
patients. But the vector proposed here was a new construct.
No animal studies were referenced. This would not have been an
unusual situation in and of itself. Many human gene transfer protocols
at this point cited the lack of availability of good animal models.
Human HIV is notorious for lack of a good animal model. However,
this issue was not addressed in the protocol.
The first of these two flags would have served as a sufficient trigger'
for many protocols reviewed by the full committee. However, reading
the protocol against the background of the federal guidelines for
research on children raised a host of other issues that seemed worthy
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•

the spectrum of preinclusion, preoperative, and follow-up screening procedures;

•

the risks associated with sedation and general anesthesia in children and specifically in HIV-positive children;

•

•

•
•

•

the risks associated with the bone marrow harvest procedure - risks
of hemorrhage or infection during or after the procedure; risks of
osteomyelitis; the possibility that small children might require
postharvest blood transfusions to replace blood and marrow lost
during the harvest;
the burden of additional hospitalization and additional medicalization of the lives of these children, including at least two
overnight hospitalizations and at least ten follow-up visits;
the risks and burdens of one bone marrow aspiration with the possibility of one to two additional aspirations;
the risks associated with the reinfusion of the genetically modified
cells, including (as stated in the consent form, Protocol p. 55)
"fever, chills, difficult breathing, and rarely, a severe allergic reaction that can lead to death";
the standard risks associated with human gene transfer, including
unpredicted vector integration leading to cancer and germ-line
issues.

Given this list, one begins with the question: Does this protocol
entail "greater than minimal risk"? For the risks to be categorized as
"minimal," as noted above, "the risks anticipated in the proposed
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research [must not be] not greater, considering probability and ma~ ·.
nitude, than those ordinarily encountered in daily life or during th"
performance of routine physical or psychological examinations or ;,
tests." Would the above present experiences that these particular chi}•.
dren would likely encounter in daily life or in the course of routine.,
examinations? Clearly not. Hence a relatively easy assessment is made '\
that this protocol presents "greater than minimal risk." If so, it must be .
considered under SS45 CFR 405, 406, or 407.
.
S45 CFR 405, as noted above, raises the question of "prospect" of~
benefit. If the risks presented by the protocol are deemed "greater than
minimal," research is approvable if it can be demonstrated that there is
a "prospect of direct benefit to the individual subjects." As the guidelines
note: "The risk is justified by the anticipated benefit to the subjects; and
the relation of the anticipated benefit to the risk is at least as favorable
to the subjects as that presented by available alternative approaches."
Therefore, to justify the more than minimal risk and burden, the
investigators in this case must be able to demonstrate that there is a
reasonable "prospect of direct benefit" to the child subjects to be
enrolled, that benefits are anticipated.
What sort of case did the investigators present? When turning to the
text of the protocol itself, one finds some rather clear clues:
Although we do not think that this initial study is likely to have a significant medical benefit for the patient, we believe that it is safe and may
provide useful information for progressing to potential beneficial treatments for AIDS. (Emphasis mine; Protocol, nontechnical abstract; similar statement included in the scientific abstract.)
While this relatively low-risk protocol is not likely to have significant
clinical benefit, it may provide useful information on the feasibility and
potential efficacy of this approach. Positive results in this study may
allow consideration of future studies entailing higher risks but higher
potential benefits. (Emphasis mine; Protocol, p. 30.)
Although patients will have routine monitoring of the disease status
performed as part of their standard clinical care, it is not a primary endpoint of the study. (Protocol, p. 25.)

The protocol is relatively clear that no benefit is anticipated to accrue
to the child subjects. Moreover, the protocol was submitted as a Phase
I clinical trial, which by definition is not designed to offer benefit.
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The audience, however, makes a difference in how the case is presented. When the investigators turn to address the RAC directly, the
above disavowals of anticipation and prospect of clinical benefit are
offset with a disclaimer about theoretical possibilities:
While the possibility of benefit from the protocol is unknown, the
potential benefits could be significant. Slowing or preventing
immunologic deterioration could be life-extending or even life-saving. (Emphasis mine; Response to NIH "Points to Consider," M-11-Al, p. 23.)
In this Phase I study, it is not known whether the subjects will receive
any benefits. The major goal of the study is to determine if this gene
therapy approach is safe and feasible in patients with HIV infection. It
is possible that the presence of the RRE decoy gene in some blood cells
will allow them to avoid active infection by HIV. This could help maintain immune function and lessen the risk of infection .... While we
have attempted to not overstate this possibility, it certainly is hoped by
the investigators that this would be the result. (Emphasis mine;
Response to NIH "Points to Consider," M-11-3, p. 26.)

Here, theory takes the place of evidence; hope has replaced warranted anticipation.
A similar shift in rhetoric appears in the Informed Consent form.
Here the emphasis on the positive possibilities becomes even more
pronounced. The first sentences of the consent form state:
You/your child [are]/is infected with human immunodeficiency virus
(HIV) and are/is eligible to participate in a medical study of gene
therapy as a possible treatment. A possible form of treatment for HIV
is gene therapy, where a new gene is put into a patient's cells .... If
the RRE decoy can bind the HIV protein, it might prevent the virus
from growing in the body. (Emphasis mine; Protocol, Informed
Consent Form, p. 49.)
It is not known whether gene therapy for HIV will be effective. It may
be difficult to get the gene into patient's bone marrow stem cells, the
gene may not be turned-on in the cells in the body, or the gene may
not actually protect the cells. The purpose of this study is to test
whether gene therapy with the RRE decoy gene can be performed safely, whether it can get the RRE decoy gene into the cells and whether
the RRE decoy gene will inhibit HIV infection of cells. (Emphasis
mine; Protocol, Informed Consent Form, p. 50.)
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The "P?te.nt~al Benefits" section of the consent form includes this
less ophm1shc assessment, but alters it significantly with the closing~
qualification:
,);

However, even though the "prospect" and "possibility" of direct
benefit to enrolled child subjects may have been remote in this case,
the research might still have been approvable under S46.406, which
allows for "research involving greater than minimal risk and no
prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subject's disorder or condition." Again,
a number of conditions obtain:

(

We do not know if there will be any direct benefits to you/your child from
participating in the study. The major goal of the study is to determine if
this gene therapy approach is safe and feasible in patients with HN infection .... If the RRE decoy gene were present in sufficient numbers of
cells, this could help maintain immune function and lessen the risk of
infection. (Emphasis mine; Protocol, Informed Consent Form, p. 51.)

The therapeutic possibilities dangle before the eyes of parents with
HIV-stricken children. What parent would not provide their child
with this chance?
The institutional IRB noted the ambiguity in this language and that
the data did not support the claim to prospect, probability, or likelihood of benefit. For this reason, upon its initial review, the IRB provided a lengthy critique of the protocol and deferred it.35
The investigators made two responses to this critique. First, they
pointed to the more positive statements above and argued that "there
is possibility of direct benefit to the subjects, if the hypotheses being
tested are found to be correct" (emphasis mine; Protocol
Investigator's Response to IRB, p. 15). The members of the IRB noted
t~~t there were a nu?1ber of "ifs" that would have to occur for possibility to accrue. The investigator notes that he and his colleagues "certainly hope" that this would be the result. However, as Kathryn
Whartenby of the FDA noted in her recommendation that this protocol receive full RAC review, there is little proof to substantiate this
statement or this hope. 36 In fact, some of the data presented in the
protocol seems to argue against clinical benefit. 37
Secondly, the investigator argued that in the nontechnical
abstract, he "thought it best to be pessimistic to not recruit patients
with false claims" (Response from Investigator, p. 6).38 This statement seems difficult to reconcile with the qualified-but-optimistic
rhetoric in the informed consent form. In other words, when addressi?g .th.e scientifi~ c.ommunity, the investigator seems to be more pess1m1shc and realistic, acknowledging that the potential benefits of this
research will accrue not to the child subjects themselves but to
progress in the battle against AIDS. When addressing reviewers and
prospective parents, however, realism gives way to hope.

The risk represents a minor increase over minimal risk;

:;
~

,

;

'

,
'
!

The intervention or procedure presents experiences to subjects that are
reasonably commensurate with those inherent in their actual or
expected medical, dental, psychological, social, or educational situations; and
The intervention or procedure is likely to yield generalizable knowledge about the subjects' disorder or condition, which is of vital
importance for the understanding or amelioration of the subjects'
disorder or condition. (Emphasis mine; S46.406.)

Here again, the open-ended nature of the terms used in the guidelines
leaves room for debate and disagreement. The easiest of these criteria
would be the second. It seems relatively clear that the procedures proposed in the protocol, namely, bone marrow aspirates and bone marrow
harvest under general anesthesia, would not normally be encountered
by HIV-positive children in the course of treatment for their disease.
Thus the procedures would not be "reasonably commensurate."
Would the protocol, however, present only a "minor" increase over
minimal risk? Here the guidelines become the most ambiguous and have
generated the most debate. The investigators argued, for example, that the
procedures did indeed represent only "a minor increase over minimal
risk" (Response of Investigators to RAC Review, p. 3) and that "the risks
and discomforts are relatively minor" (Response oflnvestigators, p. 12). In
response to critiques, the investigator stated that since the bone marrow
aspirations are performed under conscious sedation, they are "not significantly more painful than having a phlebotomy;' and that children undergoing bone marrow harvests under general anesthesia "have minimal pain
post-operatively" (Response of Investigators, p. 3).
As Janofsky and Starfield have noted, clinical experience certainly
shapes one's assessment of the magnitude and possibility of clinical
risk. 39 These investigators had performed many bone marrow procedures
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on children and experienced no adverse events; hence their assessment
of the procedures would differ radically from, say, a layperson like myself
reading about the procedures.40
·
The third and final criterion of S46.406 is that research entailing
greater-than-minimal risk without prospect of benefit to the child sub..
ject should provide generalizable knowledge of vital importance for
the understanding or amelioration of the subject's condition or disorder. But given the improbability of benefit, it was not clear to me how
the scientific and molecular findings from this trial would be of "vital"
importance to the amelioration of pediatric HIV. How ought this be
assessed? According to what criteria? Or is it the case that any findings
relative to a terrible disease with certain mortality in children count as
"vital," that is, that it is the nature of the disease rather than the nature
of the scientific findings that characterizes knowledge as vital?
Clearly, the nature and seriousness of pediatric HIV requires that
research be conducted, research that will at some point require enrollment of child subjects, perhaps earlier in the research process than
might be otherwise encouraged. However, as the NIH documents on
inclusion of children note, "their participation earlier [must be] based
on careful risk and benefit analysis."
While physiological differences between children and adults
reduce the usefulness of adult models for understanding pediatric
HIV, it was not clear that there were no points of contact. Would none
of the data from the Phase I adult HIV human gene transfer trials be
generalizable to pediatric populations? Or might some of the findings
provide at least a modicum of insight? In other words, it seemed that
certain research questions might be addressable in adults or other populations. 41 The trials approved by the RAC, however, had not yet had
time to be initiated nor had they produced any published findings.
This situation seemed to meet well the recent NIH exclusion criterion: "Insufficient data are available in adults to judge potential risk in
children (in which case one of the research objectives could be to
obtain sufficient adult data to make this judgment)."
These seemed to be the key questions, and questions on which I
wished to have more counsel. However, since the conjunction joining
the three criteria given for S46.406 is an "and," it seemed questionable
to me that this protocol could be justified under this category.42
If S46.406 remained an open question, §46.407 remained an
option. Here the guidelines provide a mechanism for "Research not

otherwise approvable, which presents an opportunity to understand,
prevent, or alleviate a serious problem affecting the health or welfare of
children." Such research might be approved by "the Secretary [for
Health and Human Services], after consultation with a panel of experts
in pertinent disciplines (for example: science, medicine, education,
ethics, law), and following opportunity for public review and comment." RAC review would be the ideal vehicle for such consultation.
This, then, was the modest conclusion that I reached in my review:
since the arguments for justification under S46.405 and S46.406
remained debatable, the protocol seemed a good candidate for the
standard process of full RAC review. Extended consideration by a
panel of persons with diverse expertise would help to settle the scientific and ethical questions. I consequently recommended, on
December 4, that the protocol ought not be exempted from full RAC
review. As the RAC was meeting on December 4 and 5, 1995, the protocol would be considered at the RAC's next meeting, in March 1996.
This recommendation, however, was declined, an artifact equally
of challenge to the guidelines and of political circumstances.43 The
March 1996 meeting of the RAC was canceled ostensibly because of
"lack of protocols to review"; clearly, by early February, the decision
had been made to approve the protocol. In early spring, the thendirector of the Office of Recombinant DNA Activity (ORDA)
announced that he was retiring from the NIH to accept a position with
the Institute for Human Gene Therapy at the University of
Pennsylvania. The June meeting of the RAC was likewise canceled. In
May, Harold Varmus, then-director of the NIH itself, unilaterally disbanded the RAC, an action that met with controversy-approbation
from some and outrage from others. In light of public response, the
RAC was later reconstituted, but in a significantly reconfigured form.
When it met again in December 1996, its authority to recommend
approval or disapproval of protocols had been stripped.

HUMAN GENE TRANSFER RESEARCH AND
CHILD SUBJECTS:

A CRITICAL JUNCTURE

The preceding analysis and narrative is not presented to suggest that the
circumstances surrounding this particular protocol have been typical of
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RAC approval of human gene transfer trials involving childre
Nonetheless, the history of this protocol, when read in light oft
guidelines governing human subjects research with children, raises' •
number of questions for both research with children in general andi
the field of human gene transfer research specifically.
.i.;
With regard to the federal guidelines and professional policies, thiai
particular protocol provides additional evidence for the increasingly,-i
perceived disjunction between well-crafted research guidelines and '
their actual implementation in the clinical research setting. Part of I;
this disjunction stems, no doubt, from the fluidity of terms and critew· ;
ria contained in the guidelines. Certainly, given the open-ended and ··
creative nature of clinical research, guidelines governing research
with human subjects ought to admit of some openness to interpreta.. ·
tion. But the regression of interpretability ought not be infinite.
As the U.S. research industry moves toward increased enrollment of
children in clinical trials, we must seriously consider how useful the fed. ·
eral guidelines will prove in ensuring that the interests of individual sub- ·.
jects are not sacrificed for the good of future children. This is especially 1
urgent for children enrolled in Phase I protocols or children enrolled as
controls, where only risks await them. It clearly falls within the purview
of the oversight and ethics community to create clarity and consensus as
far as possible. The National Bioethics Advisory Commission (NBAC)
or OPRR need to provide guidance to IRBs-which are sometimes
plagued with inexperience and at other times faced with institutional '
pressure-with regard to the interpretation and implementation of key
terms and criteria. Research ought to be conducted in the near term to
elaborate acceptable boundaries for interpreting phrases such as
"greater than minimal risk," "minor increment," "prospect of benefit,"
and "vital knowledge." These agencies ought to provide criteria for distinguishing between a benefit that is "anticipated" or "likely" and one
that is simply "possible," "hoped for," or "intended."
Such clarification would also serve to address a problem endemic
to the practice of clinical research in general, but especially troubling
with regard to research with children-the deeply problematic conflation of "research" and "treatment."44 Phase I trials, contrary to the language used in the informed consent document of the HIV protocol
above, ought not be classified as "treatment." These endeavors are
strictly scientific experiments, designed to test scientific end points

and to assess the toxicity of the compounds being administered. The
situation is clearly different with Phase II and Phase III clinical trials,
the kind specifically called for by the recent NIH and FDA rulings.
Here, the regulatory agencies require pharmaceutical companies t?
provide dosing and safety information for moieties already proven efficacious in adults. In these instances, the word "treatment" might more
reasonably be used in conjunction with the word "experiment." In
both cases, however, the OPRR ought to provide guidance to investigators and IRBs on the appropriate language to use in the informed
consent process (both the written and the face-to-face components) as
well as how to warrant "prospect" of benefit in the case of radically
new interventions. The new push to increase child enrollment in clinical trials, the political pressure exerted by parents on regulatory bodies to allow dying children the "right" to be enrolled, and the
increased financial power of the biotechnology industry converge to
make these issues urgent; unless they are addressed in the near terms,
current guidelines may prove to be little more than formalities sacrificed to expediency or desperation.
These issues remain especially urgent for the field of human gene
transfer research. The review of the HIV protocol, however, points to
an additional set of questions specific to the field. The HIV protocol
and the events surrounding the existence and purview of the RAC
from 1996 forward provided preludes to the sobering findings that
emerged from the Gelsinger case:
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•

a cavalier and obstructionist attitude on the part of industry and
many researchers toward ethical guidelines and broader oversight
of research practice;45

•

the fact that human gene transfer remains a fledgling field in
_which much basic research remains to be done;46

•

the fact that the risks of known methods of human gene transfer
have perhaps been underreported or downplayed; 47

•

the fact that risks of effective methods of human gene transfer
remain largely unknown;

•

the fact that human gene transfer's therapeutic promise remains
sadly unfulfilled ten years after initiation of the first protocol.
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Much more basic research needs to be done in order to understan(
the diverse molecular mechanisms governing the array of disord~;'
potentially amenable to gene transfer technologies. Ironically, it was just'
at the juncture when this conclusion was first publicly stated that thd.<
power of public oversight of human gene transfer research was di~c·
abled. 48 One of the main reasons given for disbanding the RAC in 1<)%:
was that it attended too much to issues of ethics; as Harold Varmus stat~. :.
ed: "the RAC had begun to exhibit a taste for trivia: it often got bogg~ ·
down in debates over the wording of patient consent forms." 49 Perhapgc •.
it is the case, however, that issues of patient well-being and the protec• "
tion of human subjects are not quite so trivial after all.
Moreover, the HIV protocol points to a global question with regard
to the field of human gene transfer as a whole. It was a Phase I prot°"'
col. Almost all of the human gene transfer protocols initiated to date,
whether with adult subjects or child subjects, have likewise been
Phase I studies. The first human gene transfer protocol began May 22,
1989. It was a "marking" protocol that accompanied an immunotherapy study in adult patients with metastatic melanoma with a life
expectancy estimated at up to 90 days. By definition, long-term risks
would be impossible to assess in this population. On February 5, 1990,
the investigators presented preliminary data from five of the first six
patients treated to that point. The second protocol, the famous SCIO.. :
ADA protocol, was approved by the RAC on July 31, 1990, and
enrolled its first patient on September 14, 1990.
This situation and the significant participation of children in the
early days of human gene transfer return us to one of the few points of
agreement noted earlier between those who hold a protectionist
stance on the issue of research on children and those who advocate a
more expansionist approach: Phase I trials in children ought to be initiated only after Phase I trials in adults have provided important indications on both safety and efficacy. Had sufficient research been
conducted by 1990 or 1993 to assess the risks that might be presented
to child subjects? Was there sufficient evidence in this phase to substantiate "prospect" of benefit from adult studies?
These are larger questions than can be entertained here. Clearly
severe combined immunodeficiency (SCIO), neuroblastoma, some of
the leukemias studied, as well as the single-gene disorders, are serious
childhood illnesses. They have no parallel in adults. But this alone does
1

·
·
50 H uman gene
not warrant their further subjection to expenmentat10n.
transfer as a proposed therapeutic modality is, a~ t?e bulk ~f the ~roto
cols and the general rhetoric surrounding genetic mterventton witnesses an intervention with potential application to a broad range of
di~eases that affiict adults as well as children. A number of the research
questions faced by early researchers in human gene transfer could have
been answered by adult studies. Hence human gene transfer seems a
logical candidate for OPRR's proposal for "tandem" research:

In some cases "tandem" studies in older populations and children may
be justifiable. For example, some Phase l studies in children might be
based on only pharmacologic safety and toxicity data \completed Phase
l and ongoing Phase 2) but without complete effectiveness data from
trials in adults and older children. If the IRB approves a Phase l drug
trial the consent document must specify what is known about the probabillty that and the degree to which, an intervention will be of possible
'
benefit based
on all of these data. 51

This however was not the route chosen by the field of human gene
transfe;. Hence ~e remain faced with an important question: How
was it that this new, untried, and controversial research endeavor
moved so quickly to the use of children as subj~cts? .
.
The preliminary answer, I will hazard at this pomt, ts as m~c~ a
matter of the sociopolitical context of NIH-funded research as it is a
matter of clinical science. Is it a coincidence that the Human
Genome Project and the field of human gene transfer research, whose
icon was a vulnerable child suffering from an incurable disease, were
launched almost simultaneously? The elaboration of that answer must
await another day.
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NOTES

overview of ethical issues in human gene transfer research; she gives little
attention to the issue of children as subjects.
6. Such a full examination is under way. Spurred by the events surrounding the RAC in 1996, I embarked on a retrospective study of human
gene transfer research involving children. This study is currently ongoing. At
this point, we have obtained copies of the approximately thirty protocols
involving children approved by the RAC from 1989 to 1996 (the point of its
hiatus) and are in the process of conducting a qualitative review of tl1ese protocols in light of the federal regulations governing research with children.
7. Robert Pear, "F.D.A Will Require Companies to Test Drugs on
Children," New York Times (November 28, 1998). The NIH issued a similar
policy, effective October 1998; see NIH Policy and Guidelines on the Inclusion
of Children as Participants in Research Involving Human Sub;ects, available
from http://grants.nih.gov/grants/guide/notice-files/not98-024.html.
8. An eighteen-year-old subject in a clinical trial targeting ornithine transcarbamylase deficiency, Jesse Gelsinger, being under twenty-one years of age,
would have qualified as a "child subject" according to certain guidelines. For
an account of the findings of tile initial inquiry at the December 8-9, 1999,
meeting of the RAC, see Sheryl Gay Stolberg, "F.D.A. Officials Fault Penn
Team in Gene Therapy Death," New York Times (December 9, 1999).
9. The current list of classic cases includes tile Tuskegee Syphilis Study,
the injection of live cancer cells into chronically ill patients, the hepatitis
studies on mentally handicapped children at Willowbrook State Hospital in
New York, Henry Beecher's expos~ of ethically suspect research published in
respected, peer-reviewed, scientific journals, controversy around research
involving live and aborted fetuses, and the U.S. radiation experiments. For an
overview of these cases in the context of Nazi experimentation and the resulting Nuremberg and Helsinki Codes, see Gregory Pence, Classic Cases in
Medical Ethics, 3rd ed. (San Francisco: Harper, 2000).
10. As historians of human subjects research know well, the basic outlines
of this tension were initially mapped in the debates between Paul Ramsey
and Richard McCormick in the early 1970s. For more on this see, among
others, Richard A. McCormick, "Proxy Consent in the Experimentation
Situation," Perspectives in Biology 6 Medicine 18 ( 1974):2-20; Paul Ramsey,
"Proxy Consent for Children," Hastings Center Report 7 (1977):4ff; Richard
A. McCormick, "Experimentation in Children: Sharing in Sociality,"
Hastings Center Report 6 (1976):41-46; Paul Ramsey, "The Enforcement of
Morals: Nontherapeutic Research on Children-A Reply to Richard
McCormick," Hastings Center Report 6 (1976):21-30.
11. Federal Register43:18 (1974), 914.
12. Federal Register 30:31 (1978), 786.

1. As Larry Churchill, et al., argue in "Genetic Research as Therapy:
Implications of 'Gene Therapy' for Informed Consent," Journal of Law,
Medicine, 6 Ethics 26:1 (1998):38-47; the phrase gene "therapy" often serves
rhetorically to mask the fact that human gene transfer interventions ought
properly to be classified as research. See also my response, "Commentary:
Reconstruing Genetic Research as Research," Journal of Law, Medicine, 6
Ethics 26: 1 (1998):48-54.
2. Michael Winerip, "Fighting for Jacob," New York Times Magazine
(December 6, 1998), recounts the story of Richard and Jordana Sontag, who
fought an emotionally excruciating political and PR battle to enroll Jacob,
afflicted with Canavan disease, in a disputed clinical trial of human gene
transfer.
3. Denise Grady, "At Gene Therapy's Frontier, the Amish Build a
Clinic," New York Times (June 29, 1999). Grady reports here on a planned
clinical trial that would enroll three Amish children in a human gene transfer protocol designed to address Crigler-Najjar syndrome, a deadly autosomal '
recessive disorder caused by the lack of a liver enzyme required for removing
bilirubin from the blood. Affected children, of whom there is a disproportionately high population within Pennsylvania Amish communities due to their
habits of intermarriage, currently combat the syndrome with high-tech light
therapy. The images are most striking.
4. A retrospective study of human gene transfer protocols with child subjects (see note 7) reveals that children were the intended subjects of 50 percent of the protocols in 1990 and of 50 to 63 percent of approved protocols
in 1991 (depending on the age limits used to define "child"). This percentage dropped in 1992 as the overall number of protocols approved began to
climb, but overall, in 1992, the total percentage of protocols enrolling children remained at 33 percent. This figure eventually leveled off and stabilized
at around 20 percent.
5. Only two articles to date come close to this issue. The first, by John C.
Fletcher, "Ethical Issues in and beyond Prospective Clinical Trials of
Human Gene Therapy," Journal of Medicine and Philosophy 10
(1985):293-309, questions the wisdom of enrolling terminally ill children in
the first trials because desperation may be used to justify unreasonable risk.
This article was written, however, five years before the first trial commenced.
The second piece seems that it would come close to this issue, given where
it appears. This is Nancy Ondrusek, "Ethical Issues in Gene Therapy," in
Ethics in Pediatric Research, ed. Gideon Koren (Malabar, Fl.: Krieger
Publishing, 1993 ), 15 5-70. However, Ondrusek's essay is simply a standard
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13. National Commission for the Protection of Human Subjects of'c
Biomedical and Behavioral Research, Report and Recommendations(,;;
Research involving Children. (Washington, D.C.: DEHW Publication No. (
(OS) 77-0004, 1977). In 1979, the commission published the landmarl,.
Belmont Report, outlining the ethical framework upon which its recommen<
dations regarding human subjects was premised. See National Commission'.'\
for the Protection of Human Subjects of Biomedical and Behavioral ',
Research, The Belmont Report: Ethical Principles and Guidelines for the. ·.
Protection of Human Subjects of Research. DHEW Publication No. (OS),·
78-0012, Appendix 1, DEHW Publication No. (OS) 78-0013, Appendix II.
(Washington, D.C.: DHEW Publication No. (OS) 78-0014, 1978).
14. 45 CFR 46, Subpart D (1983).
.
15. For those not familiar with the federal guidelines, a summary of the
components relevant to the discussion in this essay is provided here. The
complete text of S45 CFR 46 is available from http://www.med.umich.edu/
irbmed/Federa1Documents/hhs/HHS45CFR46.html.
S46.401 Exempt research
Certain research is exempt for all human subjects following specifications in S46.l 01. Exemptions include certain educational tests; the
collection of existing data, documents, records, pathological specimens, or diagnostic specimens; certain research and demonstration
projects; and tests of taste, food quality, and consumer acceptance.
S46.404 Research not involving greater than minimal risk
HHS will conduct or fund research, in which the IRB finds that no
greater than minimal risk to children is presented, only if the IRB finds
that adequate provisions are made for soliciting the assent of the children
and the permission of their parents or guardians, as set forth in S46.408.
S46.405 Research involving greater than minimal risk, but presenting
the prospect of direct benefit to the individual subjects
HHS will conduct or fund research, in which the IRB finds that
more than minimal risk to children is presented by an intervention or
procedure that holds out the prospect of direct benefit for the individual subject, or by a monitoring procedure that is likely to contribute to
the subject's well-being, only if the IRB finds that:
The risk is justified by the anticipated benefit to the subjects;
The relation of the anticipated benefit to the risk is at least as favorable to the subjects as that presented by available alternative
approaches; and
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Adequate provisions are made for soliciting the assent of the children and permission of their parents or guardians, as set forth in
S46.408.
S46.406 Research involving greater than minimal risk and no prospect
of direct benefit to individual subjects, but likely to yield generalizable
knowledge about the subject's disorder or condition.
HHS wil1 conduct or fund research, in which the IRB finds that
more than minimal risk to children is presented by an intervention or
procedure that does not hold out the prospect of direct benefit for the
individual subject, or by a monitoring procedure which is not likely to
contribute to the well-being of the subject, only if the IRB finds that:
The risk represents a minor increase over minimal risk;
The intervention or procedure presents experiences to -subjects
that are reasonably commensurate with those inherent in their
actual or expected medical, dental, psychological, social, or
educational situations;
The intervention or procedure is likely to yield generalizable knowledge about the subjects' disorder or condition, which is of vital
importance for the understanding or amelioration of the subjects'
disorder or condition; and
Adequate provisions are made for soliciting assent of the children and
permission of their parents or guardians, as set forth in S46.408.
S46.407 Research not otherwise approvable, which presents an opportunity to understand, prevent, or alleviate a serious problem affecting
the health or welfare of children
HHS will conduct or fund research that the IRB does not believe
meets the requirements of S46.404, S46.405, or S46.406, only if:
The IRB finds that the research presents a reasonable opportunity to
further the understanding, prevention, or alleviation of a serious
problem affecting the health or welfare of children, and
The Secretary, after consultation with a panel of experts in pertinent
disciplines (for example: science, medicine, education, ethics,
law), and following opportunity for public review and comment,
has determined either:
That the research in fact satisfies the conditions of S46.404, S46.405,
or S46.406, as applicable, or
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The following: (i) the research presents a reasonable opportunity to
further the understanding, prevention, or alleviation of a serious
problem affecting the health or welfare of children; (ii) the
research will be conducted in accordance with sound ethical principles; (iii) adequate provisions are made for soliciting the assent of
children and the permission of their parents or guardians, as set
forth in S46.408.
16. Jeffrey Janofsky and Barbara Starfield, "Assessment of Risk
Research on Children," Journal of Pediatrics 98 (1981):843.
17. U.S. Department of Health and Human Services, "Final Regulatiom
0
Amending Basic HHS Policy for the Protection of Human Research'.
Subjects," Federal Register46 (January 26, 1981): 8387.
18. See H. C. Shirkey, "Therapeutic Orphans," Journal of Pediatrics
( 1968): 119-20; and Robert Levine, Ethics and the Regulation of Clinical;
Research, 2nd ed. (Baltimore, Md.: Urban and Schwarzenberg, 1986),,
240-41. The term "therapeutic orphan" has shifted from its initial meaning, >
now referring more general to "orphan diseases," those so rare that therapies, ,
if developed, would not meet a significant enough market to result in profitability. Hence drug companies do not invest their resources in finding the
cause or therapies for these diseases; many single-gene disorders qualify as
"orphan diseases." See also Levine, Ethics and the Regulation of Clinical
Research: "the prevailing practice in the United States is to ignore the .
orphaning clauses on the package labels. Consequently, we have a tendency ,
to distribute unsystematically the unknown risks of drugs in children and
pregnant women, thus maximizing the frequency of their occurrence and
minimizing the probability of their detection. Parenthetically, it should be
noted that most drugs proved safe and effective in adults do not produce
unexpected adverse reactions in children; however, when they do, the num·
bers of harmed children tend to be much higher than they would be if the
drugs had been studied systematically before they were introduced into the
practice of medicine."
19. Committee on Drugs, American Academy of Pediatrics, "Guidelines
for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric '
Populations," Pediatrics 95 (1995):286.
20. Michael A. Grodin and Joel J. Alpert, "Children as Participants in
Medical Research," Pediatric Clinics of North America 35 ( 1988): 1391.
21. American Academy of Pediatrics, 286.
22. American Academy of Pediatrics, 287.
23. NIH Policy and Guidelines on the Inclusion of Children as

7l
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24. Robert Pear, "F.D.A. Requires Companies to Test Drugs on
Children," New York Times, November 28, 1998. Pear notes, "If, for example,
new drug is urgently needed to treat a life-threatening disease in children
:nd if there is no adequate therapy on the market, the Government may insist
that the manufacturer immediately begin tests in children, before full data on
adults are available."
25. The National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, Research involving Children: Report
and Recommendations (Washington, D.C.: DHEW, 1977), 2-3. In the late
1970s and early 1980s, this position was likewise echoed by the FDA and the
American Academy of Pediatrics. See Paolo L. Morselli and Francois
Regnier, "Ethics in Pediatric Research for New Antie~ileptic ~rugs," in
Antiepileptic Drug Therapy in Pediatrics, ed. P. L. Morselh, C. E. Pippenger,
and J. K. Penry (New York: Raven Press, 1983), 310.
.
26. Robert J. Levine, "Research involving Children: The National
Commission's Report," Clinical Research 26 (1978):62.
27. Department of Health and Human Services, "Additional Protections
for Children Involved as Subjects in Research," Federal Register 48
(1983):9814-20; at 9816.
.
28. Michael A. Grodin and Leonard H. Clantz, eds. Children as Research
Subjects: Science, Ethics, and Law (New York: Oxford University Press,
1994), 215.
29. American Academy of Pediatrics, 287. This recommendation is also
found in the Canadian National Council on Bioethics in Human Research,
"Revised Recommendations of the NCBHR Report on Research Involving
Children," 4 (1993):11; and the American Medical Association, Current

Opinions of the Council of Ethical and Judicial Affairs on Clinical Investigation
(1992):5. Sujit Choudhry, in his "Review of Legal Instruments and Codes on
Medical Experimentation with Children," Cambridge Quarterly of Healthcare
Ethics 3 (1994), draws as his first conclusion: "(l) There seems to be a general
consensus that pediatric research is permissible but should only be conducted
when research with adults cannot yield the same information," (570). The MP
also notes: "[The investigator] must strive to obtain as much information as possible about the safety and efficacy of a drug before enrolling children as subjects" (287). ''The investigator must be aware of possible conflicts between their
own academic, professional, and financial interests; the 'need to know'; and the
interests of the child subject" (287).
30. Available from http://ohrp.osophs.dhhs.gov/irb/irb_chapter6.htm
(April 18, 2003).
31. Donald B. Kohn, "Transduction of CD34( +) Cells from the Bone
Marrow of HIV-1 Infected Children: Comparative Marking by an RRE
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Decoy Gene and a Neutral Gene," NIH/RAC Protocol 9602-147. The pro.}
tocol itself, as well as all relevant documents referred to below, were mad~<
available as part of the public record at the December 1996 and March l 991f
RAC meetings. Copies can be requested through the Office 0£ •
Biotechnology Activities (formerly the Office of Recombinant DNA';'·
Activities; ORDA) of the National Institutes of Health. The protocol itself;:
my review, the IRB review, Kathryn Whartenby's letter, the investigator's
responses to my review and the IRB review, and the then-director of ORDA'a ;
correspondence with the investigators were included in the materials for the ·
December 1996 meeting of the RAC. My response to the director of ORDA's
correspondence was included in the meeting materials for the March 1997 ,
meeting of the RAC. Citations to these documents will be included paren-1
thetically in the text.
32. My interest in these questions stems from my work with the
Recombinant DNA Advisory Committee (RAC) of the National Institutes of ,
Health. From June 1995 to June 1998, I had the considerable privilege of
serving as a member of the RAC.
33. A word may be in order here about the responsibilities of the RAC as
well as the history and process of consolidated review. At that time, the RAC's l
charter outlined a broad scope of responsibilities for the committee, all in an
advisory capacity to the Director of the NIH and the Secretary of Health and
Human Services. As the 1994 charter stated:
Function: The Recombinant DNA Advisory Committee shall advise
the Secretary (Department of Health and Human Services), the
Assistant Secretary for Health, and the Director, National Institutes of
Health (NIH), concerning the current state of knowledge and technology regarding DNA recombinants, and recommend guidelines to be
followed by investigators working with recombinant DNA.
As noted in the NIH Guidelines for Recombinant DNA Research (51
FR 16958), the Director, NIH, must seek the advice of the
Recombinant DNA Advisory Committee before taking the following
actions: changing containment levels for types of experiments that are
not explicitly considered in the NIH Guidelines; certifying new hostvector systems; promulgating and amending a list of classes of recombinant DNA molecules to be exempt from the NIH Guidelines;
permitting experiments specified by Section III-A of the NIH
Guidelines; adopting other changes in the NIH Guidelines; interpreting and determining containment levels upon request by the Office of
Recombinant DNA Activities; revision of the Classification of Etiologic
Agents for the purposes of the NIH Guidelines.
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In the late 1970s and early 1980s, the RAC reviewed all recombinant DNA
research performed in institutions receiving federal funds for such research.
Over time, its responsibilities shifted. As data accrued regarding the relative
safety of such experiments, the RAC rather quickly transferred the bulk of the
responsibility for review to local institutional biosafety committees. With the
advent of human gene transfer in 1989, the RAC's attention shifted almost
exclusively to this new rDNA application. While continuing to advise the NIH
director about changes in the NIH guidelines concerning containment levels,
new host-vector systems, and the classification of etiologic agents, the majority
of its work in the 1990s focused on advising the director whether or not to "permit experiments specified by Section III-A of the NIH Guidelines."
The RAC provided such advice to the NIH director through protocol
review. Each human gene transfer protocol submitted to the NIH for funding was likewise submitted to the RAC. Following the practice established by
many IRBs, at this time each protocol was assigned to three primary reviewers, one of whom was to be a "nonscientist"; the reviewers would identify
questions and issues and lead the discussion of the protocol at one of the
RAC's quarterly meetings.
As one can imagine, with the first human gene transfer protocols, this
process was quite rigorous and careful. Over time, as a base ofknowledge and
experience had been laid, it was determined that many protocols raised no
new issues. Using similar vectors, similar clinical procedures, treating the
same or similar diseases, it seemed unnecessary to devote scarce committee
time to these protocols. Consequently, in 1995, the RAC instituted a policy
of "consolidated review." Each protocol submitted to the NIH would continue to be carefully reviewed by three primary reviewers (one nonscientist), but
if the reviewers deemed that the protocol presented no new issues or raised
no concerns, their review was sufficient and the protocol was exempted from
review by the full committee. If, on the other hand, the reviewers felt the protocol presented a new methodology or raised clinical, scientific, or ethical
issues worthy of further discussion, they were to recommend that the protocol be reviewed by the full committee at its next meeting.
34. The institutional IRB approved the protocol only for children aged
seven years or older.
35. Upon its initial review, the IRB at the researcher's home institution
had refused approval, citing a number of reservations in addition to the above
including:
This procedure has not been previously performed in humans.
There is no animal data because there is no animal model of human
HIV infection.
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The principal investigator states that this approach is not likely to
have clinical benefit (Protocol, p. 8).
The IRB further states: "Discussion arose about the bone marrow aspirate(s) in children for research purposes only. These children would not
receive this procedure if they were not in the research protoc~l: The ~isk is
mainly pain, however it does appear to be greater than . mm1mal r.1sk as
defined in 45 CFR 46.102 .... The investigator does not believe that this protocol provides significant clinical benefit to the subjects. Thus, one can not
justify the risks of the bone marrow aspirate(s) based on potential benefits to
the subject" (Protocol, IRB Review, 10).
36. As Whartenby notes: "The major issues associated with this protocol
are of an ethical nature: First, the use of this product in children may not be
justified, considering the invasiveness of the required procedure~ and their
associated risks. Although the investigators state that some potential for benefit may exist, there is little proof. The investigators also contend th.at benefit
may not be observed in adults, but since the purp~s~ of a p~as~ I tnal. shoul?
be to evaluate toxicity, this point may not be suff1c1ent to Justify testmg this
product in children" (Memorandum, Katherine A. Whartenby, Ph.D. to
Philip Noguchi, November 22, 1995).
37. Scientific indications against prospect of benefit are presented by two
preclinical/clinical studies the investigators presented in support of the protocol. The first is an in vitro study that demonstrates that CD34+ cells can be
isolated from cord blood and normal bone marrow, can be transduced with
anti-HIV-I vectors including the vectors proposed for use in this research, that
these vectors do not interfere with the normal function of the cell, and that
these vectors significantly suppress the replication of HIV-1 in vitro. This data
appears strong, except for one point: these in vitro cultures have been selected
by G4 l 8 for the transduced cells. The suppression of replication of HIV-1
occurs in cultures where over 70 percent of the cells have been transduced.
The investigator himself notes that "challenge of cultures with 30-'.1'0 percent
of the cells transduced, as achieved directly after gene transfer, fails to show
significant inhibition of HIV-1 probably due to the virus prod.uction by the
non-transduced cells." One might propose that the latter scenano more closely approximates the in vivo situation. Elsewhere the authors estimate that the
transduced cells will be present in vivo at a level of 1 in 10,000 or 1 percent.
The second clinical study cited was the amended SCIO-ADA protocol of
Dr. Michael Blase, involving the capture of cord blood from newborn prenatally diagnosed infants with SCIO. This cord blood was subjected ~o a
similar protocol to that proposed here: the ADA gene was transduced mto
hematopoetic stem cells, which were reinfused into the patients. This study
demonstrated that the transduced cells would engraft and that from a very
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small (in fact undetectable) number of transduced stem cells, the immune
systems of these patients could be reconstituted. It is this study that demonstrated the presence of transduced PBMCs at a level of 1 in 10,000 or
CD34( +) cells at a level of 1 percent after one year. Yet the investigators'
conclusions regarding the effects of gene expression at these levels were
unclear. While this protocol seemed to alleviate concerns surrounding the
risks of reinfusion of transduced cells, only three children had been enrolled
at that time.
Furthermore, even if this small number of transduced cells in the SCIDADA protocol was to be demonstrated to have a clinically significant effect,
the mechanism of effect for SCIO-ADA and HIV-1 inhibition seemed to be
markedly different. If the desired outcome was the production of a missing
protein, a cell population of I percent might be ~dequate. to produce sufficient quantities of the needed enzyme. However, 1f the desired outcome was
to repopulate the immune system through cell replication, a starting point of
I percent cell population seemed to have a different significance.
The investigators raised further questions regarding the significance of the
SCIO-ADA study to support the claim to prospect of benefit in their article
entitled "Engraftment of Gene-Modified Umbilical Cord Blood Cells in
Neonates with Adenosine Deaminase Deficiency," Nature Medicine 1:10
( 1995), which was included as supporting material for the protocol. Here
they stated: "The frequency of vector-containing progenitor cells exceeds by
100-fold the frequency of vector-containing cells in the mature haematopoetic cell compartments. The explanation for this dichotomy is unknown.
Potentially, the expression of the ADA gene is beneficial for progenitor cell
proliferation and allows expansion of the committed DC34+ progenitor pool
in a fashion similar to that expected for T-lymphoid progenitors. However,
the relatively high frequency of progenitor cells containing the vector is not
reflected in mature leukocytes.... This observation suggests that although
primitive progenitor cells may engraft without cytoablative therapy, they fail
to undergo complete maturation in vivo. Alternatively the presence of the
vector may interfere with mature haematopoietic cell production. Some
reports have suggested that the neomycin phosphotransferase gene (neo) may
.
.
impair hematopoietic cell function" (1021).
Thus information from the SCIO-ADA study, coupled with questions
from in vitro data on the replication of HIV-I in a culture of 40 percent transduced cells, seems to argue against the anticipation of "prospect" of benefit
for the children enrolled.
38. It appears that it was on the basis of these two responses and the claims
outlined in note 43 below that the IRB at the investigator's home institution
finally approved the protocol.

248

GENETICS AND ETHICS

39. Janofsky and Starfield, "Assessment of Risk in Research on Children."
For further description of the wide variability in the assessment of "minimal
risk" with regard to protocols involving children, see Benjamin Freedman, '
Abraham Fuks, and Charles Weijer, "In Loco Parentis: Minimal Risk as an
Ethical Threshold for Research upon Children,'' Hastings Center Report 23
(1993):13-19; and Saul Krugman's defense of the Willowbrook Hepatitis
Study in Krugman, "The Willowbrook Hepatitis Studies Revisited: Ethical
Aspects," Reviews of Infectious Diseases 8 ( 1986): 157-62.
40. I was concerned that I was perhaps allowing the names of the procedures to weigh more heavily in my assessment of their risk than they warranted. Therefore, in the process of my initial review, I consulted a handful of
individuals and colleagues in the field of pediatrics familiar with the issues of
research on children. When asked whether they would consider bone marrow aspirations and harvests in children a procedure entailing only a "minor
increa.se over minimal risk," the almost unanimous opinion was that the bone 1
marrow procedures themselves entailed significantly "greater than minimal
risk." This is certainly not a scientific sample, but it did address the concern
about clinical versus lay perceptions.
41. In my review, I suggested possible alternatives. The investigators
themselves had noted that certain scientific questions might be addressed in
SIV or SCIO/nu mice (Protocol, p. 88). They did not, however, elaborate or
show that these experiments had been conducted. I also proposed that, given
the information they provided about the physiology of pediatric HIV, an argument might be made for initially attempting this approach in HIV-positive
newborns using retrieved umbilical cord blood and either proceeding within
the neonatal period or waiting to see whether or not these infants seroconvert. This approach would test a number of the same concepts and greatly
minimize the risk and burden associated with the bone marrow process.
42. If one concludes that these children will most likely not benefit directly from this research, there are still two additional justifications for research
on children that must be considered. The first would be that children are the
only population in which this particular condition is found. While that is the
case for a disease like SCIO or PNP-deficiency, it is not the case for HIV.
Alternatively, one could argue that the physiology of children is sufficiently different from that of other human populations that research on, for example, adults will not provide helpful information. This argument is made by
the investigator. He states in response to the IRB critique that pediatric HIV
infection must be studied in children for four reasons: "(l) Pediatric AIDS
has a number of unique clinical aspects and therefore the efficacy of gene
therapy for HIV-1 infected children cannot adequately be studied in adults,
(2) the procedure may only be effective or be more effective in young chil-
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dren (e.g., <12 years old) because the level of thymic function which would
be needed for the transduced CD34+ cells to become functional T lymphocytes is greatest earliest in life (emphasis mine); and (3) gene transfer into
CD34+ cells is most effective with younger donors. [Therefore], it may be
possible that these methods would fail to show efficacy in adults and yet be
beneficial if applied to children" (Protocol, Response to IRB, 15).
A number of problems are presented by this claim. First, the investigator
makes this claim solely in the context of the response to IRB critique; except
for the first point above (which is not elaborated upon), the investigator does
not raise these issues in the context of the protocol. Moreover, neither in the
response nor in the protocol does the investigator provide any citations or
data in support of these claims. He states that pediatric HIV infection is
unique, but does not say how. He does address the second point in the protocol, but the claim is different; he states that "thymic functions, which may be
necessary for stem cells to undergo differentiation to mature T lymphocytes,
is likely to be best early in the disease course" (emphasis mine, Protocol, 33).
This is a different claim. Nor is data included on the relationship between
age and CD34+ cell transduction.
Whartenby also raises concerns relevant to these claims. As she notes:
"The investigators would like to test this product in children because of their
less developed immune system, but the protocol is written for patients aged
3-18. This age span seems to encompass more than one patient population,
since the immune system of an 18-year-old should be more similar to that of
an adult than that of a 3-year-old. Use of the older group may be more ethical, but may not provide any more information than use in adults. It is not
clear how this group should be divided or how the issue of an appropriate age
group should be handled" (Whartenby memorandum). This issue becomes
more complicated by the IRB amendment that the patient population be
restricted to children aged seven or older. Many of these children might well
not be "early in the disease course."
Finally, the investigator's third claim above is problematic as well: it certainly may be the case that a given procedure fails to show efficacy in adults
but is beneficial in children. But the investigator does not provide data to
indicate that this approach has been tried in adults and has failed. It may in
fact be the case that this approach could be tried in adults and might work.
This would provide clinical data which could be useful in informing a pediatric protocol.
43. The end of the narrative of this particular protocol may be of interest
to some. As noted above, I had submitted my review on December 4, 1995.
On February 1, 1996, I received via fax, the investigator's response to my
questions and critiques. Then, on approximately February 5, RAC members
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received notice that the March 1996 meeting had been canceled, ostensi•
bly due to "lack of protocols to discuss." It seemed apparent that my recom~
mendation had been overturned and the decision about the protocol had ,
been made. On February 8, however, I received a phone call from Dr. ,
Nelson Wivel, then-director of ORDA. As quickly became clear, Dr. Wivel
was calling to urge me to reconsider my recommendation that the protocol
go before the entire committee. Playing the card of the urgency of pediatric .
HIV research, he made it clear to me that he had greater expertise regard- ·
ing issues related to research involving children and that my concern was,
frankly, out of line. I made it clear to Dr. Wivel that I understood the justi•
fications and parameters for nonbeneficial research involving pediatric subjects, especially in the case of lethal diseases, but I also made it quite cleat
that I was not convinced that the HIV protocol met established guidelines ,
for the ethical conduct of such research. I reiterated that I had reviewed the
investigator's materials and responses thoroughly, that I had conducted a
significant amount of outside research into this question specifically in
light of this protocol, and that because of this research, I remained convinced that the protocol deserved consideration by the full RAC. I also stated that, as I had just been informed that the March meeting had been
canceled, it seemed obvious that the decision about this protocol had
already been made and that my comments and position were no longer relevant. I told him, nonetheless, that my own opinion remained unchanged.
The phone call ended.
Since the RAC did not meet again until December 1996, it was not until
this meeting that documents relevant to this protocol were made part of the
public record and circulated to members of the RAC. In those materials,
appended to the protocol, was a letter from Dr. Wivel to the principal inves·
tigator, dated February 8, 1996, the day of our phone conversation. Wivel
herein stated:
I apologize for the somewhat prolonged delay in responding to your letter and the significant amount of information that you presented in
response to the comments of Dr. Lysaught. As I think that you are well
aware, the two scientific reviewers of your protocol made the judgment
that it should be exempt from RAC review.... Your materials were forwarded to Dr. Lysaught for her review. Subsequently I had the opportunity to speak to her, and it is my assumption that she has a clearer
concept of the necessity for Phase I trials involving pediatric research
subjects who have lethal diseases, notwithstanding the fact that there
may be no benefit to a particular subject. After careful evaluation of all
the available information, it has been determined that the protocol ...
is exempt from RAC review.
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I had not been copied on this letter. One of my scientific colleagues on
the RAC, who found the tenor of the correspondence rather problematic,
brought it to my attention. My written response to this letter was made part
of the public record in the materials of the March 1997 RAC meeting.
44. Again, for more on this, see Churchill, et al., "Genetic Research as
Therapy"; and Lysaught, "Commentary: Reconstruing Genetic Research as
Research."
45. Information emerging from the continued inquiry into the practices
surrounding Jesse Gelsinger's death reveal what has been characterized as a
"95 percent failure rate" in the reporting of adverse events from investigators
conducting clinical trials of human gene transfer involving adenoviral vectors; see Sheryl Gay Stolberg, "Agency Failed to Monitor Patients in Gene
Research," New York Times, (February 2, 2000). The University of
Pennsylvania, in its official response to the RAC/FDA findings released in
December 1999, characterized the failures in their program as "little more
than 'minor deviations' in bookkeeping"; Sheryl Gay Stolberg, "Scientists
Defend Suspended Gene Therapy," New York Times, (February 15, 2000).
46. See Stuart H. Orkin and Arno G. Motulsky, National Institutes of
Health Ad Hoc Committee Report, Report and Recommendations of the

Panel to Assess the N.I.H. Investment in Research on Gene Therapy
(December 7, 1995), available from http://www.nih.gov/news/panelrep.html.
47. Paul Gelsinger, Jesse's father, reports that "he and his son had no idea
there were risks" entailed in the procedure and were not informed of adverse
events that had occurred with other subjects. Moreover, he reports that he
was told by an investigator involved with the protocol that "the treatment was
already working in some patients"; Sheryl Gay Stolberg, "Youth's Death
Shaking Up Field of Gene Experiments on Humans," New York Times,
(January 27, 2000). The FDA/NIH investigation revealed that "the informed
consent form that the investigators gave patients deviated from the one the
agency [the FDA] had approved, in that it omitted information about the
death of monkeys that had received treatment similar to that given Mr.
Gelsinger, although much more powerful"; Stolberg, "FDA Officials Fault
Penn Team in Gene Therapy Death").
48. The Orkin/Motulsky Report (see note 46 above) was issued in
December 1995, at about the time the decision was made to abolish the RAC.
49. Eliot Marshall, "Varmus Proposes to Scrap the RAC," Science 272
(1996):94 (emphasis added).
50. This point was also relevant to the HIV protocol. The investigator
noted that 80 percent of the pediatric AIDS population is African American
or Latino and that 75 percent of the younger patients followed at the investigator's institution were likewise African American or Latino. This raises social
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and ethical questions regarding whether children who are possibly already
doubly disadvantaged- socioeconomically and by their disease -are being 1
asked to assume an additional undue burden of non beneficial research. It ill
a catch-22 (if research is not conducted, this disadvantaged population is fur.- •·
ther disadvantaged by this terrible disease) unless clinical trials are designed ·
with a serious prospect of benefit.
51. Available from http://ohrp/osophs.dhhs.gov/irb/irb_chapter6.htrn ~
(April 18, 2003).
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Science, Ethics, and Policy:
Relating Human Genomics to
Embryonic Stem-Cell Research
and Therapeutic Cloning
Gerard Magill, Ph.D.
THIS CHAPTER discusses a value-based connection between the emerging technologies of human genomics, embryonic stem-cell research,
and therapeutic cloning. The goal is to provide an ethics analysis that
seeks to promote and protect society's interests in the current environment of scientific progress and technological breakthroughs.
To set the scene of the emerging capacity of bioengineering today,
I present a case study into the treatment of Molly and Adam Nash, the
first documented medical therapy to combine human genomics and
embryonic stem-cell research. My argument is that human life constitutes the most basic human value that must permeate an ethical analysis of life sciences research today. The emphasis on the value of
human life is evident in both human genomics and embryonic stemcell research, including therapeutic cloning. The breakthroughs in
human genomics raise many ethics concerns. But the first death of a
patient in a gene therapy trial in 1999 gave prominence to a profound
concern about patient safety in human genomics research. Second,
the announcement by President Bush in August 200 I permitting federal funding of research on a limited number of embryonic stem cells
generated widespread debate about the meaning of embryonic human
life. Moreover, dubious claims about a private cloning company
called Clonaid having cloned human babies in late 2002 and early
2003 have heightened the rhetoric of policy discussion about embryonic stem-cell research and human cloning. 1 Despite such claims, science continues to encounter such serious difficulties with cloning

